Abstract:To the Editor: Juvenile xanthogranuloma (JXG), the most common type of non-Langerhans cell histiocytosis (non-LCH), is generally confined to skin (cutaneous JXG [CJXG]) in children during the first 3 years of life.1Janssen D. Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry.Am J Surg Pathol. 2005; 29: 21-28Crossref PubMed Scopus (273) Google Scholar Rarely, JXG involves extracutaneous tissues or systemic organs (SJXG), resulting in higher morbidity and mortality. Activated mitogen activated protein kinase (MAPK) pathway mutations and anaplastic lymphoma kinase (ALK) translocations have been increasingly detected in subsets of histiocytosis,2Durham B.H. Lopez Rodrigo E. Picarsic J. et al.Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.Nat Med. 2019; 25: 1839-1842Crossref PubMed Scopus (82) Google Scholar but such data regarding molecular alterations in Chinese patients with JXG are lacking. We therefore retrospectively reviewed 456 pediatric patients with biopsy specimen-confirmed JXG to investigate BRAFV600E mutations and ALK translocations via digital drop polymerase chain reaction and in situ hybridization, respectively. Organ involvement in patients with SJXG was evaluated according to previously described LCH methodologies.3Haupt R. Minkov M. Astigarraga I. et al.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatr Blood Cancer. 2013; 60: 175-184Crossref PubMed Scopus (404) Google Scholar The 23 patients (5%) with SJXG presented a 1.9:1 male-to-female ratio and median age of onset at 16 months, similar to the 433 patients (95%) with CJXG (Table I). Cutaneous lesions were present in 15 patients (65.2%) with SJXG. Compared with CJXG, patients with SJXG mostly had multiple papules or nodules (n = 10; Supplementary Fig 1, available via Mendeley at https://doi.org/10.17632/528zps82wh.1), often extending to ≥2 locations, or giant skin masses (n = 3). The most common extracutaneous sites included the central nervous system (n = 11), liver (n = 9), lungs (n = 8; Supplementary Fig 2), kidney (n = 5), and hematologic involvement (n = 5; Table II). Four patients (17.4%) with SJXG died of the disease or complications.Table IComparison of systemic juvenile xanthogranuloma (SJXG) and cutaneous juvenile xanthogranuloma (CJXG)Variable∗Data are presented as the number of patients or as the median (interquartile range).CJXG (n = 433)SJXG (n = 23)P value†Based on Mann-Whitney tests for continuous variables and the Fisher exact test for categorical variables.Sex.826 Male24915 Female1848Age, mo‡Age of onset.16 (8-36)13 (4-48).594Skin lesion Solitary3132<.001 Multiple8710.015 Giant (>2 cm)333.413Locations of skin lesion Head and neck1921<.001 Trunk1122.064 Extremities782.397 ≥2 locations5110<.001Onset of skin lesion… Before systemic…3 After systemic…1 Concomitant…11BRAFV600E.002 Mutation04 Wild-type8419ALK translocation<.001 Positive08 Negative8415∗ Data are presented as the number of patients or as the median (interquartile range).† Based on Mann-Whitney tests for continuous variables and the Fisher exact test for categorical variables.‡ Age of onset. Open table in a new tab Table IICharacteristics of systemic juvenile xanthogranulomaSex/age∗Age of onset., moInitial clinical presentationsSitesALK translocation/BRAFV600E mutationTreatment/responseOutcome/duration, moF/3Solitary subcutaneous mass, ADOmentum, mesenterium, peritoneum, abdomen wallNegative/wild-typeSE/CRDF/10F/11Scattered skin nodules, DISkin, CNS, lungPositive/wild-typeCT/CRDF/26F/4Multiple skin macules and nodulesSkin, eye, liver, lung, kidney, CNSPositive/wild-typeCT/NRDOD/12F/2Fever, thrombocytopeniaSkin, liver, HI, kidney, spleenNegative/wild-typeMS/PRAWD/63M/69Pallor, AD, abdominalgiaHI, lung, liver, kidney, testicle, eye, pancreas, parotid glandPositive/wild-typeCT/CRDF/20M/at birthSolitary giant skin mass (>2 cm), thrombocytopeniaSkin, HI, liver, spleen, Lymph nodeNegative/wild-typeMS, SE/NRDOD/6M/16Fever, pancytopenia, ADHI, liver, spleen, skinNegative/wild-typeCT/NRDOH/6F/68Fever, cough, severe dyspneaLung, liver, CNS, skinPositive/wild-typeCT/PRAWD/35F/42Failure to thrive, blurred visionCNS, eyeNegative/positiveSE/PRAWD/65M/127Paralysis of both legsIntraspine (T9-T10)Negative/wild-typeSE/CRDF/2M/13Fever, pancytopenia, ADHI, BM, liver, spleen, kidneyPositive/wild-typeCT/NRDOH/6M/at birthMultiple skin nodules, giant skin massSkin, liver, lung, CNS, kidneyNegative/wild-typeMS/PRAWD/18M/13Multiple skin nodules, giant skin massSkin, cranium, lung, eyeNegative/wild-typeCT/PRAWD/15M/12Weakness, cough, feverLung, skin, pancreas, testicle, parotid glandPositive/wild-typeCT/PRAWD/14M/48HeadacheCNS, skin, craniumNegative/positiveSE/CRDF/72M/60Generalized skin nodules, DI, lamenessSkin, CNSNegative/wild-typeCT/PRAWD/105M/110Fever, vomiting, abdominaliaOmentum, mesenterium, peritoneumPositive/wild-typeCT/PRAWD/10M/18Cough, feverLung, mediastinal lymph nodesNegative/wild-typeST/SRAWD/19F/60HeadacheCNSPositive/wild-typeSE/CRDF/4F/44Multiple skin nodules, DI, orbital massCNS, cranium, skinNegative/positiveCT/PRAWD/2M/45DICNS, liver, spleen, skinNegative/positiveCT, vemurafenib/PRAWD/23M/at birthMultiple skin nodules, glaucomaSkin, eye, testicleNegative/wild-typeMS/PRAWD/10M/5Multiple skin nodules, scleral massSkin, eyeNegative/wild-typeObservation/SRAWD/13AD, Abdominal distention; AWD, alive with disease; BM, bone marrow; CT, chemotherapy; CNS, central nervous system; CR, complete response; DF, disease free; DI, diabetes insipidus; DOD, died of disease; DOH, died of hemophagocytic histiocytosis; F, female; HI, hematologic involvement; M, male; MS, monosteroid therapy; NR, no response; PR, partial response; SE, surgical excision; SR, spontaneous regression; ST, symptomatic therapy.∗ Age of onset. Open table in a new tab AD, Abdominal distention; AWD, alive with disease; BM, bone marrow; CT, chemotherapy; CNS, central nervous system; CR, complete response; DF, disease free; DI, diabetes insipidus; DOD, died of disease; DOH, died of hemophagocytic histiocytosis; F, female; HI, hematologic involvement; M, male; MS, monosteroid therapy; NR, no response; PR, partial response; SE, surgical excision; SR, spontaneous regression; ST, symptomatic therapy. Molecular alternations were present in 12 patients (52.2%) with SJXG, including 8 (34.8%) with ALK translocations and 4 (17.4%) with BRAFV600E mutations. ALK translocations and BRAFV600E mutations were mutually exclusive. Of 11 patients with central nervous system involvement, 8 (72.7%) displayed molecular alterations (4 with ALK translocation; 4 with BRAFV600E mutation), and 5 of 8 patients with lung involvement (62.5%) harbored an ALK translocation. As a control, no patients with SJXG from 2015 to 2016 (n = 84) exhibited these molecular alterations. Immunostaining for ALK and BRAFV600E supported the genetic findings. An ALK translocation occurred in 50% (2 of 4) of patients who died. SJXG and CJXG showed significant molecular differences, consistent with previous reports, but a few cases of CJXG with genetic aberrations were reported elsewhere.2Durham B.H. Lopez Rodrigo E. Picarsic J. et al.Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.Nat Med. 2019; 25: 1839-1842Crossref PubMed Scopus (82) Google Scholar These molecular alterations may be associated with systemic involvement in SJXG differently from CJXG. In SJXG, frequent ALK expression and infrequent BRAFV600E mutations were detected compared with previous reports. Recurrent ALK expression suggests a novel pathogenesis of histiocytic proliferation in SJXG. BRAFV600E mutations play a crucial role in the pathogenesis of SJXG with central nervous system involvement. Some lesions with clinical and histopathologic similarities to JXG have been considered as Erdheim-Chester disease, a rare non-LCH characterized by xanthogranulomatous infiltration of multiple organs, with activated MAPK pathway mutations, including BRAFV600E.4Emile J.F. Abla O. Fraitag S. et al.Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.Blood. 2016; 127: 2672-2681Crossref PubMed Scopus (798) Google Scholar ALK-positive histiocytosis has been proposed and shows considerable overlap with SJXG with ALK expression.5Chang K.T.E. Tay A.Z.E. Kuick C.H. et al.ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.Mod Pathol. 2019; 32: 598-608Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar Such patients share systemic involvement and may benefit from therapies targeted toward pathogenic molecular alterations. We treated a patient with BRAFV600E-mutant SJXG with vemurafenib after chemotherapy failed and achieved a satisfactory response. Furthermore, ALK-positive histiocytosis has shown responsiveness to ALK-targeted crizotinib.5Chang K.T.E. Tay A.Z.E. Kuick C.H. et al.ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.Mod Pathol. 2019; 32: 598-608Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar Limitations to our study include a small sample size and limited molecular alteration testing. Few patients with CJXG with suspected systemic involvement were radiologically examined. However, the recurrent ALK translocations detected in our study strongly suggest a novel mechanism of pathogenesis in SJXG. Molecular genetic analysis may improve precise diagnosis and management of this condition.

Abstract:Dear Editor, An 83-year-old woman developed yellow-brownish infiltrates, nodules, and tumors mimicking xanthomas, mostly involving the periorbital and chest area within three months (Figure 1). She had no abnormalities in serum cholesterol or triglycerides levels. A detailed laboratory analysis revealed the presence of mild monoclonal gammopathy with a presence of immunoglobulin G (IgG) kappa light chains; however, according to hematologist consultation, it did not require medical intervention. Imaging assessment and ultrasound examination did not show any specific involvement of internal organs. The skin biopsy demonstrated necrobiotic areas alternated with foci of xanthogranulomatous infiltration throughout the reticular dermis with extension into subcutaneous tissue. The granulomatous infiltrate was composed of epithelioid, foamy histiocytes in addition to conspicuous giant cells of the Touton type and foreign body type, as well as variable numbers of lymphocytes, plasma cells, and neutrophiles. Lipid vacuoles were seen within the foci of necrobiosis and xanthogranulomatous infiltration (Figure 2). Two months after first admission to our department, the first signs of necrosis within the lesions were noted, and massive necrosis of skin lesions occurred after the following 5 months (Figure 1). Based on the clinical manifestation and histological and laboratory findings, the diagnosis of necrobiotic xanthogranuloma (NXG) was established. In our patient, the extremely late onset of the disease, its very aggressive course, and the absence of malignant hematological disorder were remarkable. The general condition improved after local treatment and a low dose of prednisone. However, patient anamnesis revealed myocardial infarction in the past, congestive heart failure, and atrial fibrillation. Eventually, the patient died due to acute heart failure before alkylating agents could be administered; we consider the patient's death to have been unrelated to NXG. NXG is a rare, chronic granulomatous disorder which was first described in 1980 by Kossard and Winkelmann (1). Currently, less than one hundred fifty cases of this syndrome have been reported in the literature worldwide (2,3). The disease occurs during adulthood, slightly more frequently in women, and usually after the age of 60 years, although the youngest reported patient was 17 years old (3). The disease initially manifests as xanthoma-like eruptions of yellowish or red-orange papules and nodules that coalesce into indurated plaques (4). The size of the lesions typically increases over time or with the next recurrences. In comparison to hyperlipemic and normolipemic xanthomas, the lesions are firmer, more prominent, and more polymorphic (3) with superficial telangiectasias, sometimes erythematous and/or violaceous borders, and atrophy (5). Ulcerations of the lesions were observed in about 50% of patients and tended to be extensive and progressive (4). Skin lesions of NXG can occur anywhere on the body. However, about two-thirds of patients had periorbital involvement, particularly on the upper and/or lower eyelids or elsewhere on the face. The second most commonly affected site was the trunk, predominantly the chest (3-6). However, many skin lesions first appear on the trunk or extremities and subsequently involve the periorbital area (4). More than one body area was affected in about 90% of the published cases (3,4). In individual cases, the occurrence of NXG was noted within scars, after trauma, or in a previously X-ray irradiated area (5). Lesions may be asymptomatic; however, over half of patients asked reported various symptoms, predominantly itching but also burning, tenderness, and even pain (4,5). Periorbital skin lesions are often accompanied by ophthalmic manifestations, mainly scleritis, choroiditis, or conjunctivitis (3), and with complications such as blepharoptosis, restricted ocular motility, and proptosis (4,5). Extracutaneous lesions are most commonly seen in the respiratory tract, including the lungs and larynx, followed by the myocardium, oral cavity, skeletal muscles, kidneys, ovaries, intestine, and other sites (5,6). Extracutaneous involvement was reported in less than 20% of cases (3), but its frequency seems to have increased in recent years (5). Regarding laboratory abnormalities, the majority of patients with NXG (70% and up to 90% depending on the studied population) have a monoclonal gammopathy (more often IgG-kappa than IgG-lambda). Elevated erythrocyte sedimentation rate, anemia, leukopenia, low C1 and C4 levels, and cryoglobulinemia are also frequently present (3-6). Incisional biopsy is recommended to confirm the diagnosis of NXG, but correlations between the clinical presentation and specific histopathologic findings have been poorly characterized so far. The histopathology shows an inflammatory infiltrate composed of macrophages, foam cells, plasma cells, and other inflammatory cells as well as Touton and foreign body-type giant cells in the dermis and subcutaneous tissue. Necrobiosis is usually present, and nodular lymphoid aggregates are common. Cholesterol clefts or asteroid bodies are rare or absent. The epidermis may be atrophic or normal. Special stains are not helpful in establishing the diagnosis of NXG, but immunohistochemistry for CD68 is positive while it is always for CD1a and PS100 negative, like in non-X histiocytosis (4,5). In patients without a known myeloproliferative disorder, bone marrow biopsy may reveal atypical or increased plasma cells and, very rarely, true multiple myeloma (5). As mentioned above, NXG can be a manifestation of multiple myeloma. However, chronic lymphocyte leukemia, B-cell lymphoma, and other lymphoproliferative diseases have also been reported in patients with NXG (3). Remarkably, hematological disorders may emerge many years before or after the onset of skin lesions (even up to 11 years) (4). According to available literature data, the course of the disease is usually chronic and slowly progressive, and the prognosis is relatively good in the absence of co-occurrence of malignant hematological disorders ([5-7). Aside from hyperlipemic and normolipemic xanthomas, the differential diagnosis of NXG includes multifocal necrobiosis lipoidica, granuloma annulare, foreign-body granuloma, juvenile xanthogranuloma, rheumatoid nodules, and amyloidosis (4). In 5 cases from the literature, xanthoma and NXG were present at the same time (3). Despite several hypotheses, the etiopathogenesis of NXG remains unknown (3,4,8). For that reason and due to the rarity of the disease, the optimal therapy has not been not defined. Frequently, chlorambucil or melphalan have been used alone or in combination with prednisone (4). Treatment may result in remission of symptoms on the skin, but it does not provide a permanent cure (8). There are also single reports of the successful use of thalidomide, lenalidomide, cyclophosphamide, dexamethasone, interferon 2a and 2b, plasmapheresis and hydroxychloroquine, azathioprine, infliximab, and autologous bone marrow transplantation (3). Methotrexate seems to be ineffective (9). Local therapy, including local steroids, laser CO2, or radiotherapy, results in partial improvement (3,4). Skin lesions which relapsed or were unresponsive to treatment could be excised surgically and the defects resurfaced with skin grafts. [2].

PA32 A rare case of symmetrical giant facial plaque-type juvenile xanthogranuloma

Juvenile xanthogranuloma manifesting in the forehead: A case report

Ocular juvenile xanthogranuloma.

Langerhans Cell Histiocytosis Evolving into Juvenile Xanthogranuloma: Two Linked Entities

Gingival Plasma Cell Granuloma: A Case Report of Multiple Lesions

PA17 Multiple lesions in a child mimicking juvenile xanthogranulomas

Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than <i>BRAFV600E</i> mutations

A case of adolescent juvenile xanthogranuloma

P18 Giant Periocular Juvenile Xanthogranulomas Treated with Trametinib

Gastric Xanthoma Associated with Gastric Cancer Development: An Updated Review

Xanthoma-like Skin Changes in an Elderly Woman with a Normal Lipid Profile

Paediatric Orbital Juvenile Xanthogranuloma: A Case Series and Review of the Literature

Clinical Analysis of Pediatric Systemic Juvenile Xanthogranulomas: A Retrospective Single-Center Study

Juvenile Xanthogranuloma with Ocular Involvement

Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)

Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

A Systematic Review of Clinical Features and Treatment Outcomes of Xanthoma Disseminatum

Clinicopathological characteristics of xeroderma pigmentosum associated with keratoacanthoma in an infant

Uncommon Cutaneous Non-Langerhans Cell Histiocytosis Arising from Dermal Dendritic Cells in Adults: a Clinicopathological Study of Five Cases.

A Case of Verruciform Xanthoma of Labia in a Child

Juvenile xanthogranuloma manifesting with LCH‐associated neurodegenerative disease‐like radiological findings